DBV Technologies Announces Filing of 2021 Annual Report on Form 10-K and 2021 Universal Registration Document

DBV Technologies SA

Montrouge, France, March 9, 2022

DBV Technologies announces the filing of 2021 Annual Report on Form 10-K and 2021 Universal Registration Document

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announces the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, with of the United States Securities and Exchange Commission (SEC) and the filing of its 2021 Universal Registration Document (URD) ​​for the year ended December 31, 2021 with the Autorité des Marchés Financiers (AMF).

These documents are available in the Investors section of the Company’s website at www.dbv-technologies.com. In addition, the Universal Registration Document is available on the AMF’s website at www.amf-france.org and Form 10-K is available on the SEC’s website at www.sec.gov.

Printed copies of both documents are available, free of charge, at the registered office of the Company located at 177-181 avenue Pierre Brossolette 92120 Montrouge, France.

About DBV Technologies
DBV Technologies is developing Viaskin™, an exclusive research technology platform with broad potential applications in immunotherapy. Viaskin is based on Epicutaneous Immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is committed to safely transforming the care of patients with food allergies. DBV’s food allergy programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has its global headquarters in Montrouge, France, and its North American operations in Summit, NJ. The ordinary shares of the Company are listed on compartment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), which is part of the SBF120 index, and the ADSs of the Company (each representing half an ordinary share ) are listed on the Nasdaq Global Select Market (Symbol: DBVT).

Investor Contact
Anne Pollack
DBV Technologies
+1 857-529-2363
[email protected]

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
[email protected]

Attachment

Comments are closed.